Prospects and challenges of building a cancer vaccine targeting telomerase

被引:39
作者
Vonderheide, Robert H. [1 ]
机构
[1] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
关键词
telomerase; cytotoxic T lymphocyte; tumor immunology; immunotherapy;
D O I
10.1016/j.biochi.2007.07.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite their origin from self-tissue, tumor cells can be immunogenic and trigger immune responses that can profoundly influence tumor growth and development. Clinically, it may be possible to amplify or induce anti-tumor immune responses to achieve tumor rejection in patients. Increasing data over the last 8 years suggest that the human telomerase reverse transcriptase hTERT is immunogenic both in vitro and in vivo and may be a suitable target for novel cancer immunotherapy. Peptides derived from hTERT are naturally processed by tumors and presented on MHC molecules and trigger effector functions of specific T lymphocytes. Vaccination of cancer patients against hTERT epitopes induces anti-tumor T cells without clinical toxicity. If second-generation vaccines and other strategies are able to generate optimal cellular immunity against hTERT without toxicity in humans, the possibility of broad-spectrum immunotherapy or even immunoprevention therapy of cancer may be possible. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:173 / 180
页数:8
相关论文
共 92 条
[61]   A listing of human tumor antigens recognized by T cells: March 2004 update [J].
Novellino, L ;
Castelli, C ;
Parmiani, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (03) :187-207
[62]   Effector memory T cells, early metastasis, and survival in colorectal cancer [J].
Pagès, F ;
Berger, A ;
Camus, M ;
Sanchez-Cabo, F ;
Costes, A ;
Molidor, R ;
Mlecnik, B ;
Kirilovsky, A ;
Nilsson, M ;
Damotte, D ;
Meatchi, T ;
Bruneval, P ;
Cugnenc, PH ;
Trajanoski, Z ;
Fridman, WH ;
Galon, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2654-2666
[63]   Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase [J].
Parkhurst, MR ;
Riley, JP ;
Igarashi, T ;
Li, Y ;
Robbins, PF ;
Rosenberg, SA .
CLINICAL CANCER RESEARCH, 2004, 10 (14) :4688-4698
[64]   Progress in human tumour immunology and immunotherapy [J].
Rosenberg, SA .
NATURE, 2001, 411 (6835) :380-384
[65]   Cancer vaccines based on the identification of genes encoding cancer regression antigens [J].
Rosenberg, SA .
IMMUNOLOGY TODAY, 1997, 18 (04) :175-182
[66]   HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy [J].
Scardino, A ;
Gross, DA ;
Alves, P ;
Schultze, JL ;
Graff-Dubois, S ;
Faure, O ;
Tourdot, S ;
Chouaib, S ;
Nadler, LM ;
Lemonnier, FA ;
Vonderheide, RH ;
Cardoso, AA ;
Kosmatopoulos, K .
JOURNAL OF IMMUNOLOGY, 2002, 168 (11) :5900-5906
[67]   Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction [J].
Schmollinger, JC ;
Vonderheide, RH ;
Hoar, KM ;
Maecker, B ;
Schultze, JL ;
Hodi, FS ;
Soiffer, RJ ;
Jung, K ;
Kuroda, MJ ;
Letvin, NL ;
Greenfield, EA ;
Mihm, M ;
Kutok, JL ;
Dranoff, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (06) :3398-3403
[68]   Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope [J].
Schreurs, MWJ ;
Kueter, EWM ;
Scholten, KBJ ;
Kramer, D ;
Meijer, CJLM ;
Hooijberg, E .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (07) :703-712
[69]  
Schroers R, 2002, CANCER RES, V62, P2600
[70]  
Schroers R, 2003, CLIN CANCER RES, V9, P4743